Ph.D. in Chemistry in 1988 from Hebrew University in Jerusalem. Currently CEO of Boston Therapeutics, Inc., a pharmaceutical company focused on the development, manufacturing and commercialization of novel, carbohydrate-based compounds to address unmet medical needs in the areas of diabetes and inflammatory diseases. Prior to that, David was CEO of Pro-Pharmaceuticals, Inc., and SafeScience Inc.

In 1989, Dr. Platt was a research fellow at the Weizmann Institute of Science, Rehovot, Israel, and from 1989 to 1991, was a research fellow at the Michigan Foundation (re-named Barbara Ann Karmanos Institute). From 1991 to 1992, Dr. Platt was a research scientist with the Department of Internal Medicine at the University of Michigan.